Cipla Limited announced that it has been granted regulatory approval by the Drug Controller General of India (DCGI) for the launch of Favipiravir in the country under the brand name Ciplenza. The accelerated approval for manufacturing and marketing of the drug is aimed at meeting the urgent and unmet medical need for COVID-19 treatment options…
Cipla Limited and Boehringer Ingelheim India Pvt. Ltd. (BI) announced that they have entered into a partnership to co-market three new oral anti-diabetics drugs Oboravo (Empagliflozin), Oboravo Met (Empagliflozin+Metformin) and Tiptengio (Empagliflozin+Linagliptin) in India. As per the International Diabetes Federation, India is home to 77 million adults aged between 20 and 79 years with diabetes,…
Cipla Limited and Roche Products (India) Pvt. Ltd. announced that the two companies have entered into an agreement to provide better access to innovative medicines for patients in India. As part of the agreement, Cipla will be responsible for marketing and distribution of Roche Pharma’s key trademark oncology drugs viz.,Trastuzumab (Herclon), Bevacizumab (Avastin) and Rituximab…
Indian drugmaker Cipla recently announced that it will acquire a 21.85% stake in health-tech startup GoApptiv in an all cash deal. This is reportedly Cipla’s second bet on any digital healthcare startup since last year. In a stock-exchange filing, the company said it will acquire a 21.85% stake in GoApptiv for a cash consideration of…
Cipla Limited announced that it has signed a non-exclusive licensing agreement with Gilead Sciences, Inc. for the manufacturing and distribution of the investigational medicine Remdesivir, which has been issued an Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) to treat COVID-19 patients. This agreement is part of Cipla’s efforts to enhance…
The coronavirus pandemic and the concern related to the extent of damage it can cause had brought in a good degree of participation form major corporations, philanthropists, and business leaders to support the fight against the pandemic. Cipla Limited has announced an Rs 25 crore fund to support the Indian Government’s efforts to effectively combat…
Strides Pharma Science Limited (Strides) on Thursday announced that it has appointed R Ananthanarayanan as Chief Executive Officer (CEO) and Managing Director (MD). His appointment has been approved by the BoD (Board of Directors) and will be effective from January 09, 2020. R Ananthanarayanan (Ananth) will succeed Arun Kumar, Founder, and the incumbent CEO &…
Cipla Ltd. has acquired the brand name and trademark rights for Vysov & Vysov M (Vildagliptin + Metformin) of the anti-diabetic drug, Vildagliptin for the Indian market. The company has been co-marketing Vildagliptin in agreement with Novartis under brand names Vysov & Vysov M and has witnessed a strong uptake for the product in India…